Recruiting
Phase 2

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05904080

Conditions

Metastatic Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Cabozantinib S-malate

Computed Tomography

Ipilimumab

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information